Corpus Uteri, Phase II
A Phase II Evaluation of the Safety and Efficacy of Mirvetuximab Soravtansine (IMGN853) in Women With Folate Receptor-α Positive Persistent or Recurrent Endometrial Cancer
Volunteers
Health Professionals
What is the purpose of this trial?
The purpose of this study is to evaluate the activity and safety profile of mirvetuximab soravtansine (IMGN853) in patients with type II endometrial cancers that overexpress folate receptor alpha (FRα).
Help Us Discover!
You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call 877.978.8343 for more information.
Principal Investigator
Sub-Investigators
- Anca Bulgaru, MD
- Andrea Brennan
- Ashita Talsania, MRCP, MBBS
- Beverly Drucker, MD, PhD
- Blair Colette McNamara, MD
- D. Barry Boyd, MD, MS
- Elena Ratner, MD, MBA
- Gary Altwerger, MD
- Gloria Huang, MD, FACOG
- Jamie Malette
- Jessica Chow, MD
- Justin Persico, MD
- Karen Ann Hammond, DNP, APRN, ACNP (BC)
- Katherine Harvey, MD, MPH
- Kathleen Fenn, MD
- Katyayani (Katya) Papatla, MD/MPH
- Kert Sabbath, MD, FACP
- Larisa Fleysher
- M. Sung Lee, MD
- Martha Diaz
- Masoud Azodi, MD
- Megin Iaccarino
- Michael Grant, MD
- Michelle Greenman
- Nesrine Khoury
- Peter Dottino, MD, FACOG
- Rebecca Bartomeli
- Renee Moye
- Sarah Thomen, APRN
- Stacey LaRosa
- Victor Chang, MD
- Last Updated10/10/2024
- Study HIC#2000023841